5:31 PM
 | 
Oct 08, 2013
 |  BC Extra  |  Company News

J&J acquires GSK's HCV compound GSK2336805

The Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) acquired HCV compound GSK2336805 from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The HCV NS5A protein inhibitor is in Phase II development. Janssen said it plans to start Phase II trials to...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >